MedPage Today (6/14, Brown) reports that “the FDA is strengthening a warning on the labels of two diabetes drugs to reflect risk of acute kidney injuries.” The “new labels for the two sodium-glucose transport 2 (SGLT-2) drugs – canagliflozin (Invokana) and dapagliflozin (Farxiga) – will have more information about acute kidney injuries and add recommendations about how to minimize risk, said the FDA on its website” yesterday. The FDA “says that the strengthened warning comes after they have received reports of 101 confirmable cases of acute kidney injury from March of 2013 to October of” last year.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm
No comments:
Post a Comment